Scynexis Inc SCYX

$3.80 +0.14 (3.83%)

Valuation

Market cap
36,416,000
Revenue TTM
$20,600,000
Net income TTM
$-8,610,000
PE ratio
0.00
Forward PE
—
Profit margin
-41.80%
Debt to equity
0.00

Trading

Volume
54,600
Avg volume
269,986
Day's range
$3.66 – $3.90
Shares out
9,950,000
Stochastic %K
22%
Beta
1.06
Analysts
Strong Sell
Price target
$36.33

Price

Company profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fu...

Show more

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
201 884 5485
Website
https://www.scynexis.com
Address
1 Evertrust Plaza, 13th Floor, Jersey City, United States

Latest news

Stocktwits

ViktorSinclair Oct 16, 6:54 PM
$SCYX *** FRESH ALL TIME LOWS***
1 replies
yanlucas Oct 16, 2:36 PM
$SCYX I’ve gone short; I realized it’s the best approach. I’ve already made some good money—let’s keep it up!
0 replies
SeekingapeacefulpathMill Oct 16, 9:50 AM
$SCYX I like that sc247 is being considered to be used as a prophylactic against IC in high risk patients.( To me that sounds like a heck of a lot of drug needed ) ✍️ Careful about peoples who phoo phoo a good thing like a BARDA award
0 replies
LemuelPitkin Oct 15, 8:25 PM
$SCYX Re: Scy-247 In USA a new fungal brain disease Cladophialophora bantiana *rare but highly lethal black mold that primarily targets the central nervous system, creating abscesses of dead tissue and pus in the brain *four-fold increase in cases *ability to infect individuals with completely healthy immune systems *fatality rate of 60% to 70%. Will SCY-247 Be Helpful? SCY-247 shows promise: *efficacy against C. bantiana remains unproven. • Blood-Brain Barrier Penetration: Unlike many traditional antifungals, SCY-247 has been specifically designed with enhanced tissue penetration • Broad-Spectrum and Anti-Mold Profile: *activity against a wide variety of yeasts and molds • Current Development Status: The U.S. Food and Drug Administration (FDA) has granted SCY-247 Fast Track and Qualified Infectious Disease Product (QIDP) designations. *NDA submission in 2028?
0 replies
ViktorSinclair Oct 14, 9:18 PM
$SCYX Think they will do a third reverse split?
1 replies
SnapCrackleStop Oct 13, 4:49 PM
$SCYX .49 pre split. Can always get cheaper I suppose. $$$
0 replies
pantarei Oct 13, 10:50 AM
$SCYX shouled't they supposed to publish SCY-247 data in Q3?
0 replies
Biorocksme Oct 12, 11:21 PM
$SCYX Are insiders buying? Asking for a friend in moms basement trading academy
2 replies